Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 15

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 15
---
 the annual Board and committee evaluation process, including discussing evaluations with each director individually | ✓   reviews and guides agenda items for board meetings✓   encourages effective director participation by fostering an environment of open dialogue and constructive feedback among independent directors✓   involved in selection and interviewing of new Board members✓   if requested by major stockholders, ensures that they are available for consultation and direct communication as needed✓   if required, represents independent Board members externally, including in communications with stockholders and other stakeholders✓   performs such other duties as the Board may determine from time to time |

All directors are encouraged to consult with the Chairman on each of the above topics, as well. The Lead Independent Director, and each of the other directors, communicates regularly with the Chairman of the Board and Chief Executive Officer regarding appropriate agenda topics and other Board related matters. All directors, including the Lead Independent Director, are tasked with ensuring the Board appropriately exercises its risk management responsibilities and facilitate further discussion of risk matters in executive session as they deem necessary.

2025 Proxy Statement |21

| ​                                         | ​ |
| THE BOARD OF DIRECTORS AND ITS COMMITTEES | ​ |

AbbVie directors have backgrounds that when combined provide a portfolio of experience and knowledge that serve AbbVie’s governance and strategic needs. Director nominees are considered based on a range of criteria including broad-based business knowledge and relationships, prominence and excellent reputations in their primary fields of endeavor, as well as a global business perspective and commitment to good corporate citizenship, and ability to commit sufficient time and attention to the activities of the Board. They must have demonstrated experience and ability that is relevant to the Board’s oversight role with respect to AbbVie’s business and affairs. They must also be able and willing to represent the stockholders’ economic interests and satisfy their fiduciary duties to stockholders without conflicts of interest. For more details on director qualifications, please see Exhibit A to AbbVie’s Governance Guidelines. Each year, the Board and its committees conduct detailed self-evaluations covering topics such as Board and committee leadership structure, composition and effectiveness, quality of Board and committee materials and discussions, priority agenda items, schedule sufficiency, and Board processes. The evaluation forms are reviewed each year to ensure they will garner robust feedback, including on topics that are of recent interest to our investors. To ensure candid feedback, the evaluations are anonymous. The full Board, led by the Lead Independent Director, discusses the evaluation reports to determine what, if any, actions or improvements should be undertaken in the